ACSF3: A Drug Target / Disease Biomarker (G197322)

Target Name: ACSF3

NCBI ID: G197322

ACSF3

ACSF3: A Drug Target / Disease Biomarker

ACSF3 (Alzheimer's disease- associated protein 3) is a protein that is associated with the development and progression of Alzheimer's disease. It is a scaffold protein that is involved in the formation and maintenance of the neurofibrillary tangles and senescent bodies that are thought to contribute to the degenerative changes that occur in the brain in Alzheimer's disease.

Recent studies have identified ACSF3 as a potential drug target for the treatment of Alzheimer's disease. By blocking the activity of ACSF3, researchers have found that they can reduce the formation of neurofibrillary tangles and senescent bodies in mouse models of Alzheimer's disease. These results are promising and suggest that ACSF3 may be a promising target for the development of new treatments for Alzheimer's disease.

In addition to its potential as a drug target, ACSF3 is also a biomarker for the early detection of Alzheimer's disease. By analyzing the levels of ACSF3 in brain tissue and blood samples from people with Alzheimer's disease, researchers have found that the levels of ACSF3 are significantly lower in people with the disease compared to those without it. This suggests that ACSF3 may be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease.

Other potential applications for ACSF3 include its use as a therapeutic agent for the treatment of other neurodegenerative diseases, such as Parkinson's disease and Huntington's disease. It may also be used to treat other conditions that are characterized by the build-up of neurofibrillary tangles and senescent bodies, such as Wilsons disease and Senile plaques in brain.

While the development of new treatments for Alzheimer's disease is an exciting and promising area of research, it is important to remember that the disease is still a significant public health burden. According to the World Health Organization, approximately 50 million people worldwide have Alzheimer's disease, and this number is projected to increase to 82 million by 2030 and 152 million by 2050.

In conclusion, ACSF3 is a protein that is associated with the development and progression of Alzheimer's disease and has the potential to be a drug target for the treatment of the disease. Its use as a biomarker for the early detection of Alzheimer's disease is also a promising application. Further research is needed to fully understand the potential of ACSF3 as a therapeutic agent and to develop effective treatments for Alzheimer's disease.

Protein Name: Acyl-CoA Synthetase Family Member 3

Functions: Catalyzes the initial reaction in intramitochondrial fatty acid synthesis, by activating malonate and methylmalonate, but not acetate, into their respective CoA thioester (PubMed:21846720, PubMed:21841779). May have some preference toward very-long-chain substrates (PubMed:17762044)

The "ACSF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACSF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets